Diagnosis and Management of Venous Thromboembolism

Medical Clinics of North America

Volumn 92, Issue 2, 2008, Pages 443-465

  Minichiello, Tracy ^a   Fogarty, Patrick F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; UROKINASE; WARFARIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HOSPITAL ADMISSION; HUMAN; LOADING DRUG DOSE; LUNG EMBOLISM; MAGNETIC RESONANCE ANGIOGRAPHY; MORBIDITY; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

DIAGNOSTIC IMAGING; FIBRINOLYTIC AGENTS; HUMANS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 39449118656     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.12.001     Document Type: Review

References (87)

1. Heit J.A., Melton III L.J., Lohse C.M., et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 76 11 (2001) 1102-1110
2. White R.H. The epidemiology of venous thromboembolism. Circulation 107 23 Suppl 1 (2003) I4-I8
3. Silverstein M.D., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 6 (1998) 585-593
4. Horlander K.T., Mannino D.M., and Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163 14 (2003) 1711-1717
5. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 Suppl (2004) 338S-400S
6. Wells P.S., Hirsh J., Anderson D.R., et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 345 8961 (1995) 1326-1330
7. Segal J.B., Eng J., Tamariz L.J., et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med 5 1 (2007) 63-73
8. Fancher T.L., White R.H., and Kravitz R.L. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 329 7470 (2004) 821
9. Stein P.D., Hull R.D., Patel K.C., et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 140 8 (2004) 589-602
10. Brotman D.J., Segal J.B., Jani J.T., et al. Limitations of D-dimer testing in unselected inpatients with suspected venous thromboembolism. Am J Med 114 4 (2003) 276-282
11. Goldhaber S.Z., Simons G.R., Elliott C.G., et al. Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 270 23 (1993) 2819-2822
12. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 5 (1991) 933-938
13. Kearon C., Julian J.A., Newman T.E., et al. Noninvasive diagnosis of deep venous thrombosis. Mcmaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 128 8 (1998) 663-677
14. Tapson V.F., Carroll B.A., Davidson B.L., et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American thoracic society. Am J Respir Crit Care Med 160 3 (1999) 1043-1066
15. Leizorovicz A., Kassai B., Becker F., et al. The assessment of deep vein thromboses for therapeutic trials. Angiology 54 1 (2003) 19-24
16. Huisman M.V., Buller H.R., and ten Cate J.W. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med 148 3 (1988) 681-683
17. Moody A.R., Pollock J.G., O'Connor A.R., et al. Lower-limb deep venous thrombosis: direct MR imaging of the thrombus. Radiology 209 2 (1998) 349-355
18. Moser K.M., and LeMoine J.R. Is embolic risk conditioned by location of deep venous thrombosis?. Ann Intern Med 94 4 pt 1 (1981) 439-444
19. Huisman M.V., Buller H.R., ten Cate J.W., et al. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 314 13 (1986) 823-828
20. Stein P.D., Athanasoulis C., Alavi A., et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation 85 (1992) 462-468
21. Mullins M.D., Becker D.M., Hagspiel K.D., et al. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. Arch Intern Med 160 3 (2000) 293-298
22. Quiroz R., Kucher N., Zou K.H., et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA 293 16 (2005) 2012-2017
23. Musset D., Parent F., Meyer G., et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet 360 9349 (2002) 1914-1920
24. van Belle A., Buller H.R., Huisman M.V., et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 295 2 (2006) 172-179
25. Oudkerk M., van Beek E.J., Wielopolski P., et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. Lancet 359 9318 (2002) 1643-1647
26. ten Wolde M., Sohne M., Quak E., et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 164 15 (2004) 1685-1689
27. Kucher N., Rossi E., De Rosa M., et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 165 15 (2005) 1777-1781
28. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 20 (2003) 2545-2547
29. Giannitsis E., Muller-Bardorff M., Kurowski V., et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 102 2 (2000) 211-217
30. Kostrubiec M., Pruszczyk P., Bochowicz A., et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 26 20 (2005) 2166-2172
31. Hull R.D., Raskob G.E., Brant R.F., et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157 22 (1997) 2562-2568
32. Hull R.D., Raskob G.E., Brant R.F., et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med 157 20 (1997) 2317-2321
33. Hommes D.W., Bura A., Mazzolai L., et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 116 4 (1992) 279-284
34. Dolovich L.R., Ginsberg J.S., Douketis J.D., et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160 2 (2000) 181-188
35. Gould M.K., Dembitzer A.D., Doyle R.L., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130 10 (1999) 800-809
36. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 11 (2004) 867-873
37. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 18 (2003) 1695-1702
38. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 119 9 (1993) 874-881
39. Cruickshank M.K., Levine M.N., Hirsh J., et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151 2 (1991) 333-337
40. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl 3 (2004) 401S-428S
41. Prandoni P., Carnovali M., and Marchiori A. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 164 10 (2004) 1077-1083
42. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296 8 (2006) 935-942
43. van Dongen C.J., van den Belt A.G., Prins M.H., et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4 (2004) CD001100
44. Wan S., Quinlan D.J., Agnelli G., et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110 6 (2004) 744-749
45. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 3 (2001) 191-202
46. Chong B.H., Brighton T.A., Baker R.I., et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 19 3 (2005) 173-181
47. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126 2 (1997) 133-136
48. Crowther M.A., Ginsberg J.B., Kearon C., et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 159 1 (1999) 46-48
49. Voora D., Eby C., Linder M.W., et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93 4 (2005) 700-705
50. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 13 (2002) 1690-1698
51. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 22 (2005) 2285-2293
52. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5 4 (2005) 262-270
53. Millican E., Jacobsen-Lenzini P.A., Milligan P.E., et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110 5 (2007) 1511-1515
54. Kreit J.W. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 125 4 (2004) 1539-1545
55. Konstantinides S., Geibel A., Heusel G., et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347 15 (2002) 1143-1150
56. Mewissen M.W., Seabrook G.R., Meissner M.H., et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 211 1 (1999) 39-49
57. Elsharawy M., and Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial. Eur J Vasc Endovasc Surg 24 3 (2002) 209-214
58. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 10 (2002) 3484-3488
59. Segal J.B., Streiff M.B., Hoffman L.V., et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 146 3 (2007) 211-222
60. Trujillo-Santos J., Herrera S., Page M.A., et al. Predicting adverse outcome in outpatients with acute deep vein thrombosis. findings from the RIETE registry. J Vasc Surg 44 4 (2006) 789-793
61. Kovacs M.J., Anderson D., Morrow B., et al. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 83 2 (2000) 209-211
62. Prandoni P., Lensing A.W., Prins M.H., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 4 (2004) 249-256
63. Kolbach D.N., Sandbrink M.W., Hamulyak K., et al. Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 1 (2004) CD004174
64. Junger M., Diehm C., Storiko H., et al. Mobilization versus immobilization in the treatment of acute proximal deep venous thrombosis: a prospective, randomized, open, multicentre trial. Curr Med Res Opin 22 3 (2006) 593-602
65. Partsch H., Kaulich M., and Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol 23 3 (2004) 206-212
66. Partsch H., and Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 32 5 (2000) 861-869
67. Hann C.L., and Streiff M.B. The role of vena caval filters in the management of venous thromboembolism. Blood Rev 19 4 (2005) 179-202
68. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338 7 (1998) 409-415
69. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 3 (2005) 416-422
70. Ray Jr. C.E., Mitchell E., Zipser S., et al. Outcomes with retrievable inferior vena cava filters: a multicenter study. J Vasc Interv Radiol 17 10 (2006) 1595-1604
71. Lopez J.A., Kearon C., and Lee A.Y. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program (2004) 439-456
72. Murchison J.T., Wylie L., and Stockton D.L. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 91 1 (2004) 92-95
73. Piccioli A., Lensing A.W., Prins M.H., et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2 6 (2004) 884-889
74. Levine M.N., Hirsh J., Gent M., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74 2 (1995) 606-611
75. Schulman S., Rhedin A.S., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332 25 (1995) 1661-1665
76. Eichinger S., Weltermann A., Minar E., et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 164 1 (2004) 92-96
77. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 7 (2003) 631-639
78. Ridker P.M., Goldhaber S.Z., and Glynn R.J. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 349 22 (2003) 2164-2167 author reply 2164-7
79. Prandoni P., Lensing A.W., Prins M.H., et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137 12 (2002) 955-960
80. Palareti G., Legnani C., Cosmi B., et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87 1 (2002) 7-12
81. Palareti G., Legnani C., Cosmi B., et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108 3 (2003) 313-318
82. Eichinger S., Minar E., Bialonczyk C., et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290 8 (2003) 1071-1074
83. Palareti G., Cosmi B., Legnani C., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 17 (2006) 1780-1789
84. Grifoni S., Vanni S., Magazzini S., et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 166 19 (2006) 2151-2156
85. Fanikos J., Stapinski C., Koo S., et al. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 94 4 (2004) 532-535
86. Bond C.A., and Raehl C.L. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy 24 8 (2004) 953-963
87. Dager W.E., Branch J.M., King J.H., et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother 34 5 (2000) 567-572